title: Experience with the use of salazosulfapyridine for intractable diarrhea after hematopoietic stem cell transplantation.
abstract: We encountered 2 children with intractable diarrhea after allogeneic hematopoietic stem cell transplantation (SCT). In both cases, salazosulfapyridine (SASP) was administered to treat the diarrhea. One patient was a 14-year-old male with acute myelogenous leukemia who received SCT from a related HLA-identical donor. The leukemia recurred early, and a second SCT from the same donor was performed approximately half a year later. Because intestinal graft-versus-host disease (GVHD) was observed, steroids and octreotide were administered, but the symptoms were not improved. Thereafter, SASP was administered, and the symptoms remitted 9 days later. The other patient was a 12-year-old male with chronic myelogenous leukemia who received SCT from an unrelated HLA-identical donor. Diarrhea and abdominal pain developed early after engraftment and did not respond to either steroids or tacrolimus. Oral administration of SASP was initiated on day 236, and the diarrhea remitted 4 days later without recurrence thereafter. SASP may be effective in children for the digestive system symptoms of chronic GVHD.
authors.affiliation: Department of Pediatrics, Sakai Hospital, Kinki University School of Medicine, Osaka, Japan. naohiko@sakai.med.kindai.ac.jp
authors.forename: Naohiko
authors.initials: N
authors.lastname: Moriguchi
authors.forename: Sadayuki
authors.initials: S
authors.lastname: Isokawa
authors.forename: Atsushi
authors.initials: A
authors.lastname: Ando
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Miyata
mesh_terms: D000293:Adolescent; D003967:Diarrhea / Q000188:drug therapy* / Q000209:etiology; D006086:Graft vs Host Disease / Q000150:complications / Q000188:drug therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D013256:Steroids / Q000008:administration & dosage; D012460:Sulfasalazine / Q000008:administration & dosage*; D016559:Tacrolimus / Q000008:administration & dosage
chemical_list: D007166:Immunosuppressive Agents; D013256:Steroids; D012460:Sulfasalazine; D016559:Tacrolimus